Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
Rationale Recently, a CDC advisory Committee on Immunization Practices identified a likely association between the 2 COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna and cases of myocarditis and pericarditis. For the cardiovascular system, 4863 adverse events (AEs) were reported from the Pfizer vaccine. Common findings observed with vaccines under study were tachycardia(16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.6%), and increased heart rate (9.03%). In this study we characterized, classified, evaluate the dynamic of cardiac function and ECG abnormality after the Pfizer vaccine injection.
This is a prospective cohort study. All participants aged 13-18 years old and above who visited the second dose Pfizer covid-19 vaccine injection to determine cardiac manifestation.
Methods for analyzing research data The data will be collected from students enrollment at Kong thabbok upatham changkol kho so tho bo school and Wachirathamsatit school. The participant's history, physical exam, and laboratory data will be reviewed and data will be extracted based on the case record form (CRF). All data will be stored securely and analyzed using the SPSS® Statistics Version 23 developed by IBM®. Data entry will be carried out using coding and verification. Quantitative data will be expressed as mean with standard deviation (SD) or median (IQR) and qualitative data will be presented as a number of observations with percentage (%). Descriptive statistics will be used to summarize the baseline values and demographic data.
All p-values will be derived using the 2-tailed testing, and statistical significance will be set at 0.05 probability. All the categorical variables will be analyzed using the chi-square (x2) or Fisher's exact test whichever is appropriate. Normality of the distribution will be tested for the continuous variable using the Kolmogorov- Smirnov test. All the variables with normal distributions will be compared using the independent t-test and will be reported as mean ± standard deviation (SD). The variables that do not pass the normality test will be compared by means of the Mann-Whitney U test and will be reported as the median and interquartile range (IQR).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Data Collection Methods
- Participants' demographics will be collected at baseline using case record form.
- Laboratory tests include: at 3 clinical visits (Baseline, Day3, Day7 and Day 14 (optional if have cardiac manifestation) after 2nd dose of Pfizer COVID-19 vaccine) 2.1. Cardiac biomarker (Troponin-T, CK-MB) 2.2. Echocardiography 2.3. ECG (Electrocardiography)
After getting approval from the Ethics Committee and before the start of the trial, the study team informed the interesting participants about the study by invitation letter with ZOOM or line meeting. Informed consent printed to the parents who interested in this project and bring to the team investigator before enrollment. A contact address and phone number will be provided for the interesting participants to call for more information about the study.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
BAngkok, Thailand, 10400
- Faculty of Tropical Medicine
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Student age 13-18 who received 1st dose of pfizer COVID-19 vaccine from
- Kong thabbok upatham changkol kho so tho bo school
- Wachirathamsatit school
Beskrivning
Inclusion Criteria:
- Age 13-18 years old
- Both males and females
- Received 1st dose Pfizer COVID-19 vaccine injection
Exclusion Criteria:
- Unable to obtain written informed consent from the participants or their legal representatives
- History of cardiomyopathy, tuberculous pericarditis, and constrictive pericarditis
- Severe allergic reaction to COVID-19 vaccine
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at baseline
Tidsram: Day 0
|
cardiac manifestation defined as sinus tachycardia, hypertension at baseline
|
Day 0
|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 3
Tidsram: Day 3
|
cardiac manifestation defined as sinus tachycardia, hypertension at day 3
|
Day 3
|
|
Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 7
Tidsram: Day 7
|
cardiac manifestation defined as sinus tachycardia, hypertension at day 7
|
Day 7
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at baseline
Tidsram: Day 0
|
frequency (%) of participant with myocarditis at baseline
|
Day 0
|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 3
Tidsram: Day 3
|
frequency (%) of participant with myocarditis at day 3
|
Day 3
|
|
Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 7
Tidsram: Day 7
|
frequency (%) of participant with myocarditis at day 7
|
Day 7
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at baseline
Tidsram: Day 0
|
frequency (%) of participant with pericarditis at baseline
|
Day 0
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 3
Tidsram: Day 3
|
frequency (%) of participant with pericarditis at day 3
|
Day 3
|
|
Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 7
Tidsram: Day 7
|
frequency (%) of participant with pericarditis at day 7
|
Day 7
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at baseline
Tidsram: Day 0
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at baseline
|
Day 0
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 3
Tidsram: Day 3
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 3
|
Day 3
|
|
Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 7
Tidsram: Day 7
|
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 7
|
Day 7
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Chayasin Mansanguan, M.D., Mahidol University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Cardiac and pfiizer
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid-19 vaccin
-
Stanford UniversityViamoAvslutadKunskap om COVID-19-vaccin | Covid-19 vaccin troFörenta staterna
-
EyeGene Inc.Novotech (Australia) Pty LimitedAktiv, inte rekryterande
-
University of WashingtonCenters for Disease Control and PreventionRekryteringCovid-19 | Vaccin tveksamhetFörenta staterna
-
Masaryk UniversityRekryteringBiverkningar på vaccin | Covid-19 vaccinPolen, Kanada, Förenta staterna, Kroatien, Tjeckien, Estland, Etiopien, Tyskland, Ghana, Mexiko, Portugal, Ryska Federationen, Serbien, Slovenien
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Duke University och andra samarbetspartnersAvslutadVaccin tveksamhet | Covid-19 vaccinFörenta staterna
-
Korea University Guro HospitalAjou University School of Medicine; Korean Center for Disease Control and... och andra samarbetspartnersRekryteringInflammation | Vaccin biverkning | Vaccin immunsvar | Covid-19-vaccinationKorea, Republiken av
-
Chulalongkorn UniversityNational Vaccine Institute, Thailand; Chula Vaccine Research Center (ChulaVRC)... och andra samarbetspartnersAvslutad
-
Cancer Institute and Hospital, Chinese Academy...RekryteringCovid-19 vaccin | Covid-19 infektionKina
-
Mahidol UniversityClinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...AvslutadCovid-19 infektion | COVID-19 VACCINThailand
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical... och andra samarbetspartnersAvslutadLunginflammation, Viral | Covid-19 vaccin | COVID-19 sjukdom | SARS lunginflammationVietnam
Kliniska prövningar på Diagnostic of ECG
-
Sohag UniversityHar inte rekryterat ännuTic Disorder, barndomEgypten
-
Hoffmann-La RocheFoundation MedicineRekryteringMetastaserande lungcancer | Metastaserande mag-tarmcancerSpanien, Frankrike, Italien, Nederländerna, Tyskland
-
UMC UtrechtRadboud University Medical Center; University Medical Center Groningen; Amsterdam...RekryteringÄrftlig hjärtsjukdomNederländerna
-
Complexo Hospitalario Universitario de A CoruñaAvslutad
-
Karolinska University HospitalRoche DiagnosticsAktiv, inte rekryterande
-
Anumana, Inc.Mayo ClinicHar inte rekryterat ännuVentrikulär ejektionsfraktionFörenta staterna
-
University of PisaFondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, ItalyRekryteringGraviditetskomplikationer | Graviditetsrelaterad | Preeklampsi | Fostrets tillväxthämning | Fosterkomplikationer | Graviditetsdiabetes | Graviditetssjukdom | EKG ElektrodplatsreaktionItalien
-
University of Campania "Luigi Vanvitelli"Avslutad
-
Foundation for Innovative New Diagnostics, SwitzerlandKenya Medical Research InstituteHar inte rekryterat ännuVisceral leishmaniasis